Q2 2026 Spero Therapeutics, Inc. Earnings Call Transcript
Key Points
- FDA approval of Utebzi, the first oral carbapenem antibiotic, provides a significant commercial milestone and potential revenue stream through GSK partnership.
- In-licensing of SP001, a third-generation anti-CD40L antibody, diversifies pipeline into high-unmet-need immunology, with potential across multiple autoimmune indications.
- Closed $105 million non-dilutive, non-recourse royalty financing, strengthening balance sheet and extending cash runway into the second half of 2029.
- Appointment of Dr. Debra Zack as CMO brings deep immunology expertise, enhancing clinical development capabilities for SP001.
- SP001's mechanism targeting CD40L offers a differentiated approach by modulating upstream immune activation, potentially addressing multiple disease pathways in IgG4-RD.
- No revenue recorded in Q2 2026, down from $14.2 million in Q2 2025, due to completion of prior collaboration agreements.
- Net loss widened to $9.6 million in Q2 2026 from $1.7 million in Q2 2025, reflecting increased expenses and lack of revenue.
- SP001 is still in early clinical stages, with Phase 2 trial not expected to begin until Q2 2027, indicating a long path to potential commercialization.
- The royalty financing carries a 10% annual interest rate and nine-year maturity, with payments derived solely from Utebzi milestones/royalties, which may be uncertain.
- Dependence on GSK's successful launch and sales of Utebzi for future royalty income, which is subject to market and regulatory risks.
Good afternoon and welcome to the Spero Therapeutics second quarter 2026 earnings conference call. Please be advised that this call is being recorded and a replay will be available. You can find the information on the replay and further information related to today's announcement on the Spero Therapeutics website at SperoTX.com.
At this time, I would like to turn the call over to Shai Biran, Head of Investor Relations. Mr. Biran, please go ahead.
Thank you, operator, and thank you all for participating in today's conference call. This afternoon, Spero Therapeutics released financial results and provided a business update for the second quarter of 2026. A press release is available on the investor page of the Spero Therapeutics website.
Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. These forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
